On November 9, 2017 GlycoMimetics, Inc. (Nasdaq:GLYC) reported that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows (Press release, GlycoMimetics, NOV 9, 2017, View Source [SID1234521869]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

STIFEL 2017 HEALTHCARE CONFERENCE
When: November 14, 2017 at 8:00 a.m. ET
Where: New York, NY, USA
JEFFERIES 2017 LONDON HEALTHCARE CONFERENCE
When: November 16, 2017 at 3:20 p.m. GMT
Where: London, UK

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

On November 9, 2017 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) reported that its management will be presenting at the Jefferies 2017 London Healthcare Conference in London, UK, at the German Equity Forum in Frankfurt, Germany, and at the Annual Berenberg European Conference in Surrey, UK, and will be attending DZ BANK Equity Conference in Frankfurt, Germany, and dbAccess Pharmaceutical and Healthcare Corporate Day in London, UK (Press release, Evotec, NOV 9, 2017, View Source [SID1234521864]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2017 London Healthcare Conference, London, UK
Date: Thursday, 16 November 2017, 11.20 am GMT (12.20 pm CET, 06.20 am EST)
Webcast: Click here for the webcast
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

DZ BANK Equity Conference, Frankfurt, Germany
Date: Wednesday, 22 November 2017
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

German Equity Forum, Frankfurt, Germany
Date: Monday, 27 November 2017, 11.30 am CET (10.30 am GMT, 05.30 am EST)
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

dbAccess Pharmaceutical and Healthcare Corporate Day, London, UK
Date: Thursday, 30 November 2017
Venue: London, UK
Attendee: Enno Spillner, Chief Financial Officer of Evotec AG

Annual Berenberg European Conference, Surrey, UK
Date: Wednesday, 06 December 2017, 09.45 am GMT (10.45 am CET, 04.45 am EST)
Venue: Surrey, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

On November 9, 2017 Pfenex Inc. (NYSE AMERICAN: PFNX), reported that it will be presenting at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th at 12:40 pm GMT / 7:40 pm ET (Press release, Pfenex, NOV 9, 2017, View Source2017-11-09-Pfenex-Inc-to-Present-at-the-Jefferies-2017-London-Healthcare-Conference" target="_blank" title="View Source2017-11-09-Pfenex-Inc-to-Present-at-the-Jefferies-2017-London-Healthcare-Conference" rel="nofollow">View Source [SID1234521896]). The presentation will be webcast and available for replay in the Investors Section of Pfenex’s website at www.pfenex.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (View Source), our investor relations website (View Source), press releases, SEC filings, public conference calls, corporate Twitter account (View Source), Facebook page (View Source), and LinkedIn page (View Source) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

On November 9, 2017 Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ("Prima") reported the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead product candidate, in combination with pembrolizumab (KEYTRUDA) in unresectable or metastatic melanoma patients (Press release, Prima Biomed, NOV 9, 2017, View Source [SID1234521897]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data will be presented in the poster titled "Pushing the accelerator and releasing the brake: testing the soluble LAG-3 protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma" (Poster Number P259) for the first time at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2017 Annual Meeting, to be held on November 10-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. Eftilagimod alpha, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses.

"The data to be presented at the SITC (Free SITC Whitepaper) meeting is very encouraging and demonstrates that anti-tumor activity was observed in patients following the administration of eftilagimod alpha in combination with pembrolizumab. Furthermore, it is important to note that prior to coming into this study, these patients were treated with pembrolizumab monotherapy and did not achieve a meaningful therapeutic benefit from this treatment," stated Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer.
The patients eligible to participate in the TACTI-mel Phase 1 clinical trial are those that have either had a suboptimal response or had disease progression with KEYTRUDA monotherapy as a first-line of treatment. 12 patients from the first two cohorts of the trial were treated with 1 and 6mg doses of eftilagimod alpha respectively. The third cohort of patients, being treated with 30 mg doses, is ongoing.

Dr. Frédéric Triebel further commented, "The data also supports the hypothesis that there is a therapeutic synergy when administering an APC activator, which enhances anti-tumor T cell production, in combination with a checkpoint inhibitor, which releases the brake on the T cells."

The presentation at the SITC (Free SITC Whitepaper) conference includes the following results:

• Combination of eftilagimod alpha (1 and 6 mg) and pembrolizumab in advanced metastatic melanoma patients is safe and well tolerated;
• Anti-tumor activity (tumor reduction) was observed in 7/12 patients (58 %) in this study; prior to the study all of these patients either had a suboptimal response or had disease progression when treated with the pembrolizumab monotherapy;

• Data presented supports the hypothesis that combining an APC activator (IMP321) with a checkpoint inhibitor (pembrolizumab) results in a therapeutic synergy and a potential clinical benefit over a checkpoint inhibitor monotherapy;

• Data presented supports further investigation of IMP321 in combination with PD-1/ PD-L1 checkpoint inhibitors in different tumor types.

Marc Voigt, Prima’s Chief Executive Officer, added, "We believe the positive data, taken together with the excellent safety profile of eftilagimod alpha and data from our ongoing clinical trial in metastatic breast cancer, further validate the therapeutic utility of modulating the LAG-3 immune control mechanism. We are very pleased with the clinical progress of eftilagimod alpha and look forward to presenting additional data from the TACTI-mel clinical trial and exploring the potential therapeutic benefit of combining it with other checkpoint inhibitors in other solid tumors."
A copy of this SITC (Free SITC Whitepaper) poster presentation is available on Prima’s website in the Presentations section of the Investors tab at View Source

On November 9, 2017 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update for the Company, and host investor meetings at the following three conferences (Press release, Supernus, NOV 9, 2017, View Source [SID1234521905]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2017 Healthcare Conference
Date: Tuesday, November 14, 2017
Time: 11:45 a.m. EST
Place: Lotte New York Palace Hotel, New York

Jefferies 2017 London Healthcare Conference
Date: Thursday, November 16, 2017
Time: 4:40 p.m. GMT (11:40 a.m. EST)
Place: Waldorf Hilton, London, U.K.

Piper Jaffray 29th Annual Healthcare Conference
Date: Wednesday, November 29, 2017
Time: 8:00 a.m. EST
Place: Lotte New York Palace Hotel, New York

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com. An archived replay of these webcasts will be available for 60 days on the Company’s website after each conference.